DDrare: Database of Drug Development for Rare Diseases

Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 15 or 45 mg; 30 or 60 mg; 30 or 90 mg; AL; AMIAS; AMLODIPINE; APRINOX; Acetate; Amias; Aminohippurate; Aminohippurate Sodium Inj 20%; Amlodipine; Anti-hypertensive medications; Antihypertensive drugs; Aprinox; Arginine; BARDOXOLONE METHYL; BENDROFLUMETHIAZIDE; BIM 23014; BISOPROLOL; BOSUTINIB; Bardoxolone; Bardoxolone Methyl; Bardoxolone methyl; Bardoxolone methyl 10 mg; Bardoxolone methyl 15 mg; Bardoxolone methyl 20 mg; Bardoxolone methyl 5 mg; Bardoxolone methyl capsules; Bardoxolone methyl oral capsule; Behavioral: Diet and water adjustment; Bendroflumethiazide; Bisoprolol; Bosutinib; Bosutinib (anhydrous); C03XA01; CANDESARTAN; CARDURA; Calcineurin inhibitors maintenance; Candesartan; Candesartan and Cilnidipine; Candesartan plus non-CCB agents; Certican; Certican Tabletten; Cilnidipine; Conventional therapy; Curcumin; DOXAZOSIN; Doxazosin; Emodin; Equal; Everolimus; G1117337; GENZ-682452; GLPG2737; GZ402671; Genz-682452-AU; HCT; High water intake; Hydralazine; Hydrochlorothiazide; ISTIN; Imidapril; Intravenous injection autologous mesenchymal stem cells; Iohexol; Iohexol Inj 300 milligrams per milliliter (MG/ML); Istin; JINARC - 15 MG +45 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28X15 MG + 28 X 45 MG); JINARC - 15 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE; JINARC - 30 MG + 60 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 60 MG); JINARC - 30 MG +90 MG - COMPRESSA - USO ORALE - BLISTER(ALU/PVC) IN CONFEZIONE A PORTAFOGLIO - 56 COMPRESSE (28 X 30 MG + 28 X 90 MG); JINARC - 30 MG - COMPRESSA - USO ORALE - BLISTER (ALU/PVC) - 28 COMPRESSE; Jinarc; Jinarc - Tolvaptan tablets; Jinarc 15 mg tablets, Jinarc 45 mg tablets; Jinarc 30 mg tablets, 90 mg tablets; Jinarc 30 mg tablets, Jinarc 60 mg tablets; Jinarc® 15mg Tablet; Jinarc® 30 Tablet; KD019 (tesevatinib); LANREOTIDE ACETATE; LISINOPRIL; Lanreotide; Lisinopril; Lixivaptan; Long-acting somatostatin; Losartan; METFORMIN; METFORMINA; MONOCOR; Metformin; Metformina; Monocor; NG-Monomethyl-L-arginine; Ng-monomethyl-L-arginine (drug); Niacinamide; OPC-41061; OPC-41061 (tolvaptan); Octeotride; Octreotide; Octreotide LAR; Octreotide-LAR; Other: Ad libitum water intake; Other: High Water Intake; Other: Low Blood Pressure Control; Other: Saline solution; Other: Saline solution.; Other: Standard; Other: Standard Blood Pressure Control; Other: Water; Other: Water prescription; Other: water; PF-05208763; Pasireotide; Pasireotide LAR; Pioglitazone; Placebo; Potassium; Pravastatin; Procedure: renal sympathetic denervation; Protein; RAD001; RAPAMUNE*100CPR RIV 1MG; RAPAMUNE*30CPR RIV 1MG; RAPAMUNE*30CPR RIV 2MG; RGLS4326; RTA 402; Radiation: PET/CT Scan; Ramipril; Rapamune; Rapamune 1mg tablets; Rapamycin; SANDOSTATINA - LAR 20 MG/2.5 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE FLACONE POLVERE + SIRINGA PRERIEMPITA 2.5 ML + 2 AGHI; SANDOSTATINA LAR; SAR402671, GZ402671 or GZ/SAR402671; SIROLIMUS; SKI-606; Saline; Samsca; Samsca 15 mg tablets; Samsca 30 mg tablets; Sandostatin LAR; Sandostatina; Sandostatina LAR; Sandostatina Lar IM Fl 20mg +2F; Sirolimus; Sodium citrate; Sodiumchloride; Somatostatin; Somatuline; Somatuline Autogel; Somatuline Autosolution; Spironolactone; Sugar pill; TOLVAPTAN; TOLVAPTAN (OPC-41061); TOLVAPTAN 15; TOLVAPTAN 30; TOLVAPTAN 45/15; TOLVAPTAN 60/30; Telmisartan; Tesevatinib; Tetracosactin; Tolvaptan; Tolvaptan (OPC-41061); Tolvaptan 15 mg Tablet; Tolvaptan 15 mg tablets; Tolvaptan 15mg; Tolvaptan 30 mg Tablet; Tolvaptan 30 mg tablets; Tolvaptan 30mg; Tolvaptan 7.5 mg Tablet; Tolvaptan IR; Tolvaptan MR; Tripterygium; Tripterygium Wilfordii; Tripterygium wilfordii; Triptolide; Triptolide-Containing Formulation; UDCA; URSOCHOL 300; Unknown; Ursochol; Ursodeoxycholic Acid; Ursodeoxycholic acid; Venglustat; Venglustat GZ/SAR402671; Venglustat GZ402671; Water; ZESTRIL; ZUGLIMET - 500 MG COMPRESSE RIVESTITE CON FILM 30 COMPRESSE IN BLISTER PVC/AL; [METFORMINA]; [TOL; [TOLVAPTAN 15]; [TOLVAPTAN 30]; [TOLVAPTAN 45/15]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02127437 (ClinicalTrials.gov)	September 19, 2014	2/4/2014	Lanreotide In Polycystic Kidney Disease Study	Lanreotide In Polycystic Kidney Disease Study	Autosomal Dominant Polycystic Kidney Disease (ADPKD	Drug: Lanreotide;Drug: saline	Assistance Publique - Hôpitaux de Paris	IPSEN pharmaceutical company, Boulogne-Billancourt, France	Completed	18 Years	N/A	All	159	Phase 3	France
2	NCT01616927 (ClinicalTrials.gov)	June 2012	6/6/2012	Study of Lanreotide to Treat Polycystic Kidney Disease	The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Lanreotide	University Medical Center Groningen	Leiden University Medical Center;Erasmus Medical Center;Radboud University	Active, not recruiting	18 Years	60 Years	All	300	Phase 3	Netherlands
3	EUCTR2011-005017-37-NL (EUCTR)	30/05/2012	21/05/2012	To investigate the effect of Lanreotide on renal function decline in ADPKD patients	A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study	First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume. MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Somatuline Autogel Product Name: Lanreotide Product Code: BIM 23014 INN or Proposed INN: Lanreotide Other descriptive name: LANREOTIDE ACETATE	DIPAK Consortium	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
4	NCT01354405 (ClinicalTrials.gov)	May 2011	13/5/2011	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)	The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease	Polycystic Liver Disease	Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	70 Years	Both	43	N/A	Netherlands
5	NCT00771888 (ClinicalTrials.gov)	April 2008	13/10/2008	Open-Label Extension of LOCKCYST Trial	Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers	Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney;Autosomal Dominant	Drug: lanreotide	Radboud University	Ipsen	Active, not recruiting	18 Years	88 Years	Both	54	Phase 2;Phase 3	Belgium;Netherlands
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00565097 (ClinicalTrials.gov)	October 2007	28/11/2007	Lanreotide as Treatment of Polycystic Livers	Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers	Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney, Autosomal Dominant	Drug: Placebo;Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	88 Years	Both	38	Phase 2;Phase 3	Belgium;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02127437
(ClinicalTrials.gov)

September 19, 2014

2/4/2014

Lanreotide In Polycystic Kidney Disease Study

Autosomal Dominant Polycystic Kidney Disease (ADPKD

Drug: Lanreotide;Drug: saline

Assistance Publique - Hôpitaux de Paris

IPSEN pharmaceutical company, Boulogne-Billancourt, France

Completed

18 Years

N/A

All

159

Phase 3

France

NCT01616927
(ClinicalTrials.gov)

June 2012

6/6/2012

Study of Lanreotide to Treat Polycystic Kidney Disease

The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Drug: Lanreotide

University Medical Center Groningen

Leiden University Medical Center;Erasmus Medical Center;Radboud University

Active, not recruiting

18 Years

60 Years

All

300

Phase 3

Netherlands

EUCTR2011-005017-37-NL
(EUCTR)

30/05/2012

21/05/2012

To investigate the effect of Lanreotide on renal function decline in ADPKD patients

A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study

First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume.
MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Trade Name: Somatuline Autogel
Product Name: Lanreotide
Product Code: BIM 23014
INN or Proposed INN: Lanreotide
Other descriptive name: LANREOTIDE ACETATE

DIPAK Consortium

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Netherlands

NCT01354405
(ClinicalTrials.gov)

May 2011

13/5/2011

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease

Polycystic Liver Disease

Drug: Lanreotide

Radboud University

Ipsen

Completed

18 Years

70 Years

Both

N/A

Netherlands

NCT00771888
(ClinicalTrials.gov)

April 2008

13/10/2008

Open-Label Extension of LOCKCYST Trial

Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers

Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney;Autosomal Dominant

Drug: lanreotide

Radboud University

Ipsen

Active, not recruiting

18 Years

88 Years

Both

Phase 2;Phase 3

Belgium;Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00565097
(ClinicalTrials.gov)

October 2007

28/11/2007

Lanreotide as Treatment of Polycystic Livers

Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers

Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney, Autosomal Dominant

Drug: Placebo;Drug: Lanreotide

Radboud University

Ipsen

Completed

18 Years

88 Years

Both

Phase 2;Phase 3

Belgium;Netherlands